Search results | merck serono

Reports

Partnering Agreements with Merck KGaA

This report provides all the information you require to better understand Merck KGaA / Merck Serono and its partnering interests and activities over the past seven years.

Insights

Merck Serono partnering

Merck Serono is a subsidiary of Merck KgaA

Partnering with Merck KgaA / Merck Serono: Your best partner

Merck KgaA / Merck Serono is a top pharma company active in partnering, licensing and M&A in biopharmaceuticals, consumer healthcare and research equipment

Merck KGaA / Merck Serono: Company Profile

Merck KGaA, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years

Merck Serono and CORPAK MedSystems in pharma partnering pact for gastroenterology operation

A pharma partnering agreement was signed between CORPAK MedSystems &  Merck Serono Limited, a big pharma company whereby  CORPAK will acquire the gastroenterology sales and distribution operation of Merck Serono Limited in the UK and Ireland

Merck Serono: External “innovation machine” feeds the pipeline

Written and published by partneringNEWS 

Merck Serono expects M&A to build China sales

Merck Serono AG, the biopharma arm of German chemical and pharma giant Merck KGaA, plans to use M&A to grow its presence in China.

Merck KgaA partnering

Merck KGaA is a top pharmaceutical company based in Darmstadt, Germany

Merck hunts for smaller drug developers for acquisition

German healthcare group Merck KGaA is looking for acquisitions and collaborations with start-ups to grow its drugs business in the United States, a senior Merck official said.

Merck KGaA: Partnering activity 2005-2013

Merck KGaA and Merck Serono announced over 136 partnering / licensing deals since 2005, with 28 deals in 2007 alone. Analysis of the partnering deals shows a strong emphasis on partnerships in oncology

Merck KGaA: M&A activity 2005-2013

Merck KGaA has announced 8 M&A deals since 2005, with the lead deal being the acquisition of Serono

Events

Sorry, your search returned no results.


Deals

Merck Serono and Intrexon in CAR-T cancer pact

Intrexon and Merck Serono announced an exclusive strategic collaboration and license agreement to develop and commercialize Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies

Merck Serono and Illumina in oncology diagnostic pact

Illumina has formed a collaboration with Merck Serono to develop a universal next-generation sequencing (NGS)-based oncology diagnostic

Big pharma, Merck Serono joins hand with Lupin to expand its product portfolio

Big pharma, Merck Serono announced the establishment of a long-term strategic partnership with Lupin Limited.

Auxogyn collaborates with big pharma Merck Serono

Auxogyn announced an exclusive license agreement with big pharma, Merck Serono for Auxogyn’s proprietary Early Embryo Viability Assessment (Eeva) Test.

Merck Serono signs a pharma licensing deal with BeiGene

Merck Serono announced that a global pharma licensing, co-development, and commercialization agreement for BeiGene-290 has been signed with BeiGene for $232 million.

Merck Serono in pharma deals with ObsEva for preterm labor compounds licensing

ObsEva announced the closing of a CHF 32 million Series-A financing round and licensing pharma deals with Merck Serono.

Merck Serono pharma partners Life Technologies for companion diagnostics collaboration

Life Technologies Corporation signed agreement to collaborate with pharma partners Merck Serono for current and future companion diagnostic projects.

Merck Serono Ventures nets $77.4 in financing facility from Merck KGaA

Merck announced that it will increase its commitment to its strategic corporate venture capital fund Merck Serono Ventures to € 100 million of financing.

Merck Serono big pharma deals Quintiles in clinical co-development agreement

Merck Serono big pharma deals with Quintiles in a new, five-year clinical co-development agreement.

BMS and Merck Serono enter diabetes drug pharma partnering

Merck Serono announced a pharma partnering agreement for promotion of the type 2 diabetes drug Glucophage (metformin hydrochloride) under different formulations in China.